Top Markets
Coin of the day
Liminal BioSciences Inc. Liminal BioSciences Inc.

Liminal BioSciences Inc.

LMNL
Rank in Stocks #38949
Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm,... Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammatory, fibrotic, and metabolic diseases, with its operations spanning Canada and the United Kingdom. Its flagship drug candidate, fezagepras (identified as PBI-4050), has successfully advanced through Phase I clinical trials. This agent, along with its related derivatives, is undergoing investigation for potential application in treating idiopathic fibrosis affecting the lungs, liver, heart, or skin, as well as various respiratory conditions. Furthermore, Liminal is advancing antagonist programs, including G-protein coupled receptor 84 (GPR84) and Oxo-eicosanoid receptor 1 (OXER1), both of which are currently in preclinical development. Formerly known as Prometic Life Sciences Inc., the company adopted the name Liminal BioSciences Inc. in October 2019. Established in 1994, its corporate headquarters are located in Laval, Canada.
Share Price
$8.50
Last synced: 2023-09-26
Market Cap
$719.10K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
CA
Trade Liminal BioSciences Inc. (LMNL)

Category

Stock price history for Liminal BioSciences Inc. (LMNL)
Highest end of day price: $8.45 on 2023-09-01

Lowest end of day price: $1.69K on 2009-12-01
Stock price history of Liminal BioSciences Inc. from 2009 to 2026
Annual Stock Price Performance
Year Performance
2023 112.62%
2022 -61.46%
2021 -76.57%
2020 -35.75%
2019 -97.45%
2018 -73.89%
2017 -28.49%
2016 -38.09%
2015 36.88%
2014 102.93%
2013 334.33%
2012 40.83%
2011 23.59%
2010 -34.41%
2009 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$506.54 29.78%
US
$843.80 29.33%
NL
$729.87 6.86%
CH
$1.07K -6.40%
KR
$252.41 11.51%
BE